Hemolysin1gm/5ml
Type:Injection
Generic Name:Aminocaproic Acid
Manufacturer:Chemist Laboratories Ltd.
Price:৳0.00
Indication
Intravenous Treatment and prophylaxis of haemorrhage Adult: Initially, 4-5 g as a 2% solution over 1 hr followed by a 1 g/hr infusion continued for up to 8 hr or until bleeding has been controlled. Max: 24 g in 24 hr. Oral Treatment and prophylaxis of haemorrhage Adult: Initially, 4-5 g, followed by 1-1.25 g every hr for about 8 hr or until bleeding has been controlled. Max: 24 g in 24 hr. Patients with haemophilia undergoing dental extraction Adult: Initially, 6 g immediately after the procedure, followed by 6 g every 6 hr for up to 10 days.
Administration
Increased risk of hypercoagulability with OC and oestrogens.
Adult Dose
Renal or cardiac disorders. Urinary tract bleeding, haematuria of upper urinary tract origin; veno-occlusive hepatic disease, skeletal myopathy, neonates. Monitor creatinine phosphokinase. Avoid admin with factor IX complex concentrates. Pregnancy and lactation. Lactation: not known whether excreted in breast milk, use caution
Renal Dose
Aminocaproic acid inhibits the action of plasminogen activators and, to a lesser extent, it also has some antiplasmin activity.
Mode of Action
IV Administration Initial 5 g in 250 mL over 1 hr, each subsequent gram in 50-100 mL at 1 g/hr Rapid injection undiluted into a vein is not recommended Continue for about 8 hr or until bleeding has been controlled Oral May be taken with or without food. May be taken w/ meals to prevent GI upset.
Precaution
Haemorrhage, Missed abortion, Hereditary hemorrhagic telangiectasia,Traumatic hyphema, Dental bleeding, Hemophilia A, Postoperative bleeding, Systemic hyperfibrinolysis
Side Effect
Renal impairment: Dosage reduction may be required.
Pregnancy Category Note
Oedema, headache, malaise, allergic and anaphylactic reactions, anaphylaxis, bradycardia, hypotension, peripheral ischaemia, thrombosis, abdominal pain, diarrhoea, nausea, vomiting, agranulocytosis, coagulation disorder, leukopaenia, thrombocytopaenia, increased CPK, muscle damage, myalgia, myopathy, myositis, rhabdomyolysis, confusion, convulsions, delirium, dizziness, hallucinations, intracranial hypertension, stroke, syncope, dyspnoea, nasal congestion, pulmonary embolism, pruritus, rash, tinnitus, decreased vision, watery eyes, increased BUN, dry ejaculation. Potentially Fatal: Cardiac and hepatic damage.
Interaction
Bleeding due to disseminated intravascular coagulation. Rapid IV administration.
